Utah Medical Products | 10-Q: FY2025 Q3 Revenue: USD 9.812 M

Revenue: As of FY2025 Q3, the actual value is USD 9.812 M.

EPS: As of FY2025 Q3, the actual value is USD 0.82.

EBIT: As of FY2025 Q3, the actual value is USD 1.892 M.

Segment Revenue

• Labor & Delivery: $1,039 in 3Q 2025, $3,089 in 9M 2025.
• Gynecology/Electrosurgery/Urology: $4,954 in 3Q 2025, $14,656 in 9M 2025.
• Neonatal: $2,176 in 3Q 2025, $6,261 in 9M 2025.
• Blood Pressure Monitoring and Accessories: $1,643 in 3Q 2025, $5,469 in 9M 2025.

Operational Metrics

• Net Income: $2,631 in 3Q 2025, $8,720 in 9M 2025, representing a decrease of 26.2% and 20.5% respectively compared to the same periods in 2024.
• Gross Margin: 57.1% in 3Q 2025, 56.8% in 9M 2025, down from 58.0% and 59.3% in the respective periods of 2024.
• Operating Income: $2,611 in 3Q 2025, $8,961 in 9M 2025, reflecting a decline of 21.9% and 16.0% respectively from 2024.
• Operating Margin: 26.6% in 3Q 2025, 30.4% in 9M 2025, compared to 33.4% and 33.6% in the same periods of 2024.

Cash Flow

• Operating Cash Flow: $11,215 in 9M 2025, compared to $11,894 in 9M 2024.
• Free Cash Flow: Not explicitly stated, but net cash used in financing activities was $10,367 in 9M 2025.

Unique Metrics

• Adjusted EBITDA: $4,170 in 3Q 2025, $13,493 in 9M 2025, showing a decrease of 15.9% and 12.7% respectively from 2024.

Future Outlook and Strategy

• Core Business Focus: UTMD plans to introduce high-pressure process control transducer configurations to biopharmaceutical manufacturers and continue leveraging OUS distribution and manufacturing synergies.
• Non-Core Business: The company remains vigilant for affordable accretive acquisition opportunities and plans to utilize positive cash generation for dividends and share repurchases.
• Priority: Management expects 2025 revenues to be 6-7% lower than 2024, with EPS projected in the range of $3.40-3.50.